Septerna (SEPN) Profit After Tax (2023 - 2026)
Septerna (SEPN) posted quarterly Profit After Tax of -$1.2 million for Q1 2026, up 94.48% year-over-year from -$609839.0 in Q1 2025, and up 97.59% quarter-over-quarter from -$49.2 million in Q4 2025.
Septerna (SEPN) Profit After Tax (2023 - 2026) Analysis & Trends
Septerna's Profit After Tax history runs 4 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 94.48% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$66.9 million (up 15.73% YoY), while the FY2025 annual figure was -$48.9 million, up 31.89% from the prior year.
- Profit After Tax for Q1 2026 stood at -$1.2 million, up from -$49.2 million in the prior quarter.
- The five-year high for Profit After Tax was $34.9 million in Q4 2023, with the low at -$49.2 million in Q4 2025.
- The 4-year median for Profit After Tax is -$16.5 million (2024), against an average of -$12.4 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax slumped 159.74% in 2024, then soared 140.79% in 2025.
- Septerna's Profit After Tax stood at $34.9 million in 2023, then plunged by 159.74% to -$20.8 million in 2024, then tumbled by 136.13% to -$49.2 million in 2025, then soared by 97.59% to -$1.2 million in 2026.
- Business Quant data shows SEPN's Profit After Tax at -$1.2 million in Q1 2026, -$49.2 million in Q4 2025, and $8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Septerna | 2.08 Bn | 2.08 Bn | - | -13.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.73 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | -49.22 Mn |
| Sep 30, 2025 | 8.37 Mn |
| Jun 30, 2025 | -24.84 Mn |
| Mar 31, 2025 | -21.48 Mn |
| Dec 31, 2024 | -20.84 Mn |
| Sep 30, 2024 | -20.52 Mn |
| Jun 30, 2024 | -16.51 Mn |
| Mar 31, 2024 | -14.10 Mn |
| Dec 31, 2023 | 34.89 Mn |
| Sep 30, 2023 | -10.95 Mn |